Back to top
more

Amedisys (AMED)

(Real Time Quote from BATS)

$96.22 USD

96.22
52,955

-0.58 (-0.60%)

Updated Nov 8, 2024 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Swarup Gupta headshot

5 Stocks to Gain as Fed Chair "Blinks" on Rates

by Swarup Gupta

Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.

Amedisys (AMED) Up 7.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What Falling Estimates & Price Mean for DaVita (DVA)

by Zacks Equity Research

DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

Why Amedisys (AMED) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Amedisys (AMED).

Bright Outlook for Outpatient and Home Healthcare Industry

by Zacks Equity Research

Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.

Zacks.com highlights: Robert Half International, Children' Place, Amedisys, Foot Locker and Comfort Systems USA

by Zacks Equity Research

Zacks.com highlights: Robert Half International, Children's Place, Amedisys, Foot Locker and Comfort Systems USA

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Sanghamitra Saha headshot

5 Quality Stock Picks Screened on DuPont Analysis

by Sanghamitra Saha

Bet on five top-ranked stocks with higher ROE derived the DuPont way.

5 Low Leverage Stocks You Can Safely Add to Your Portfolio

by Zacks Equity Research

One should keep in mind that debt financing remains a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate

Is Amedisys (AMED) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

4 Quality Stocks to Counter Market Volatility

by Zacks Equity Research

With the markets currently facing a lot of gyration, investing in quality stocks seems prudent. After all, these stocks provide excellent risk-adjusted returns.

Swarup Gupta headshot

US Stocks Enjoy Highest Post-Midterm Gains Since 1982: 5 Picks

by Swarup Gupta

A large swathe of market watchers thinks that a gridlocked Congress will be beneficial for U.S. equity markets.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for November 7th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Zacks.com highlights: Core-Mark Holding, CACI International, Amedisys, Cadence Design Systems and WNS Holdings

by Zacks Equity Research

Zacks.com highlights: Core-Mark Holding, CACI International, Amedisys, Cadence Design Systems and WNS Holdings

The Zacks Analyst Blog Highlights: Archer-Daniels-Midland, Best Buy, Heidrick & Struggles International, Amedisys and RH

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Archer-Daniels-Midland, Best Buy, Heidrick & Struggles International, Amedisys and RH

5 Top-Ranked Momentum Stocks Driven by Driehaus Strategy

by Zacks Equity Research

Investors who have the tendency to take a high level of risks can choose momentum stocks using Driehaus strategy.

Sanghamitra Saha headshot

5 Top-Ranked Stocks Driven by DuPont Analysis

by Sanghamitra Saha

Here's why you should have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.

    Tirthankar Chakraborty headshot

    Winning November to Make Up for a Spooky October: 5 Picks

    by Tirthankar Chakraborty

    With November all set to dispel the darkness of October, investing in fundamentally sound stocks that are poised to gain in the near term seems judicious.

    Zacks.com highlights: Werner Enterprises, Amedysis, Haverty Furniture, Energen and MGIC Investment

    by Zacks Equity Research

    Zacks.com highlights: Werner Enterprises, Amedysis, Haverty Furniture, Energen and MGIC Investment

    Tirthankar Chakraborty headshot

    New Strong Buy Stocks for November 1st

    by Tirthankar Chakraborty

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

    5 Low Leverage Stocks to Secure Your Portfolio Amid Volatility

    by Zacks Equity Research

    One should keep in mind that debt financing remains a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate.

    Amedisys (AMED) Tops Earnings and Revenue Estimates in Q3

    by Zacks Equity Research

    At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues in Q3.

    Company News For Oct 30, 2018

    by Zacks Equity Research

    Companies In The News Are: CTB,MCY,AMED,RHT,IBM

    Amedisys (AMED) Q3 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Amedisys (AMED) delivered earnings and revenue surprises of 23.38% and 1.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?